New in Breast Cancer Therapeutics

PURPOSE: Long-term outcomes of patients with stage I human epidermal growth factor receptor 2 (HER2)-positive breast cancer receiving adjuvant trastuzumab emtansine (T-DM1) remain undefined, and prognostic predictors represent an unmet need. ͏    ͏    ͏    ͏    ͏    ͏    ͏    ͏    [SYNOPSI logo] [Dr image] Rosana Gnanajothy, MD Breast Medical Oncologist Hematology Oncology Physician Monday, August 12, 2024 “Outstanding” efficacy for adjuvant T-DMI in the final 5-year results in the ATEMPT trial in Stage I HER2+ breast cancer; and proof of the value of HER2DX genomic testing in ID’ing patients with a higher risk of recurrence. For triple-negative breast cancer, the presenting stage appears to be prognostic for overall survival; and new data open up the possibility of using stromal tumor-infiltrating lymphocytes to help de-escalate therapy. And important news from two negative trials: The Phase III AMEERA-5 study looked at amcenestrant as a possible partner for palbociclib instead of letrozole in stage IV ER+ breast cancer; and there was no benefit to adding everolimus to adjuvant endocrine therapy in high-risk early-stage breast cancer, although it’s possible it could still be helpful for premenopausal patients. Journal of Clinical Oncology [Adjuvant Trastuzumab Emtansine Versus Paclitaxel Plus Trastuzumab for Stage I Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: 5-Year Results and...]( Annals of Surgical Oncology [Impact of Presenting Stage on Overall Survival in Patients Treated with Neoadjuvant Chemotherapy for Triple Negative Breast Cancer.]( JAMA Oncology [Tumor-Infiltrating Lymphocytes in Patients With Stage I Triple-Negative Breast Cancer Untreated With Chemotherapy.]( Journal of Clinical Oncology [Randomized Phase III Study of Amcenestrant Plus Palbociclib Versus Letrozole Plus Palbociclib in Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advance...]( Journal of Clinical Oncology [Phase III Randomized, Placebo-Controlled Trial of Endocrine Therapy ± 1 Year of Everolimus in Patients With High-Risk, Hormone Receptor-Positive, Early-Stage Breast Cancer.]( [A Property of Everyday Health group] © 2024 Everyday Health Media, LLC. MedPage Today is among the federally registered trademarks of MedPage Today, LLC, and may not be used by third parties without explicit permission. You have received this email because you have registered to receive emails at www.medpagetoday.com, with the email address: {EMAIL} [Manage Email Preferences]( | [Unsubscribe](lst=Non Sold MPT Condition Alert_Oncology) | [Terms of Use]( | [Privacy Policy]( Technical Questions: feedback@medpagetoday.com 114 5th Avenue, 15th Floor New York, NY 10011